SAT0388 CHARACTERIZATION OF PATIENTS WITH PSORIATIC ARTHRITIS AND NAIL PSORIASIS: DATA FROM THE CORRONA PSORIATIC ARTHRITIS/SPONDYLOARTHRITIS (PSA/SPA) REGISTRY
Authors: Philip J. Mease, Peter Hur, Mei Liu, Sabrina Rebello, Robert Mclean, Blessing Dube, Meghan Glynn, Alexis Ogdie
Journal: Annals of the Rheumatic Diseases (2019)

<h3>Background</h3> Nail disease is an important feature of PsA and may even precede the disease by many years.<sup>1</sup> Nail psoriasis is considered one of the 6 disease domains of PsA<sup>2</sup>; however, there have been limited real-world studies that have examined characteristics of patients with PsA and nail psoriasis, particularly in the United States. <h3>Objectives</h3> To characterize the disease activity, quality of life, and work productivity of patients with PsA with and without nail psoriasis in the US-based Corrona PsA/SpA Registry. <h3>Methods</h3> This study included all patients in the Corrona PsA/SpA registry enrolled between March 2013 and October 2018 with a diagnosis of PsA who had non-missing data on physician-reported nail psoriasis. Patients were stratified by presence vs absence of nail psoriasis at the time of enrollment, defined as a non-zero response on the nail psoriasis visual analog scale (VAS) of 0–100. Descriptive analyses of patient demographics, disease activity, quality of life, and work productivity were assessed at enrollment and compared between nail psoriasis groups using <i>t</i>-tests or Wilcoxon rank-sum tests for continuous variables and χ<sup>2</sup> or Fisher's exact tests for categorical variables. <h3>Results</h3> A total of 2841 patients with PsA met the inclusion criteria, including 1152 patients (40.5%) with nail psoriasis and 1689 patients (59.5%) without nail psoriasis at enrollment. Patients with and without nail psoriasis were similar in terms of demographic and clinical characteristics; however, patients with nail psoriasis were slightly younger (53.1 vs 54.4 years) and more likely to be male (51.9% vs 44.1%) and have a higher history of depression (17.8% vs 13.3%) compared with patients without nail psoriasis (all <i>P</i> &lt; 0.05). Patients with nail psoriasis had more severe psoriasis and PsA disease activity, as reflected by statistically significantly higher percentage of affected body surface area (BSA), higher tender and swollen joint counts, decreased likelihood of being in minimal disease activity, worse mean Disease Activity in Psoriatic Arthritis (DAPSA) and Psoriatic Arthritis Disease Activity Score (PASDAS) values, and increased likelihood of having enthesitis and dactylitis at enrollment compared with patients without nail psoriasis (<b>Table 1</b>; all <i>P</i> &lt; 0.05). Patients with nail psoriasis had worse self-reported physical function (HAQ-DI), pain, fatigue, EQ-5D scores, and work and activity impairment compared with patients without nail psoriasis (<b>Table 2</b>; all <i>P</i> &lt; 0.05). <h3>Conclusion</h3> PsA patients with nail psoriasis at the time of registry enrollment had worse disease activity, quality of life, and work productivity compared with those patients without nail involvement. These findings emphasize the importance of identification and management of nail disease in patients with PsA. <h3>References</h3> [1] Gladman DD, et al. Ann Rheum Dis. 2005;64(suppl 2):ii14-7. [2] Coates LC, et al. Arthritis Rheumatol. 2016;68(5):1060-71. <h3>Acknowledgement</h3> This study was sponsored by Corrona, LLC. Corrona is supported through contracted subscriptions with multiple pharmaceutical companies. The abstract was a collaborative effort between Corrona and Novartis, with financial support provided by Novartis. <h3>Disclosure of Interests</h3> Philip J Mease Grant/research support from: AbbVie, Amgen, BMS, Celgene, Janssen, Lilly, Novartis, Pfizer, SUN and UCB, Consultant for: AbbVie, Amgen, BMS, Galapagos, Gilead Sciences, Inc., Janssen, Lilly, Novartis, Pfizer, SUN and UCB, Speakers bureau: AbbVie, Amgen, BMS, Celgene, Genentech, Janssen, Lilly, Novartis, Pfizer and UCB, Peter Hur Employee of: Peter Hur is an employee of Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, USA, Mei Liu Employee of: M. Liu is an employee of Corrona, LLC., Sabrina Rebello Employee of: Corrona, LLC, Robert McLean: None declared, Blessing Dube Employee of: B. Dube is an employee of Corrona, LLC., Meghan Glynn Employee of: M. Glynn is an employee of Corrona, LLC., Alexis Ogdie Grant/research support from: (To my university) Novartis, Pfizer, Grant/research support from: Novartis, Pfizer, Grant/research support from: Novartis, Pfizer, Grant/research support from: Novartis, Pfizer, Consultant for: AbbVie, Bristol-Myers Squibb, Celgene, Corrona, Eli Lilly and Company, Novartis, Pfizer, and Takeda, Consultant for: AbbVie, Amgen, Bristol-Myers Squibb, Celgene, Corrona, Eli Lilly, Novartis, Pfizer Inc, Takeda, Consultant for: Abbvie, Amgen, BMS, Celgene, Corrona, Lilly, Novartis, Pfizer, Takeda, Consultant for: Abbvie, Amgen, BMS, Celgene, Corrona, Lilly, Novartis, Pfizer, Takeda